Advertisement
This round was led by the leading life science venture capital fundsYSIOS Capital Partners, LSP (Life Science Partners) and Ventech. GrupoGenetrix also played a key role in the deal, and two of Cellerix' currentinvestors (Roche Venture Fund and Novartis Venture Fund) have significantlyincreased their stake. Furthermore, A&G and Cellerix' management team havealso subscribed to the capital increase. Florent Gros (representing Novartis)and a second representative from Genetrix, still to be designated will joinCellerix board of directors.
Advertisement
The new Cellerix shareholders include Bankinter S.A., Capital RiesgoMadrid and JV Risk Technologies S.L.
Joel Jean-Mairet, Cellerix's Chairman has commented "The size of thisround and the quality of the participants show investor's confidence in thepotential of Cellerix and its management team. Cellerix is becoming a worldreference in the emerging cell therapy area as it moves towards the marketlaunch of its first product backed by a very interesting pipeline".
The funds raised by Cellerix in this financing round will be used forfunding the completion of the clinical development of its lead product -Ontaril(R) - and preparation for its market launch in H2 2011. The proceedsof the round will also be used for funding the development additionalproducts in the pipeline, including allogenic programs for the treatment ofthe autoimmune diseases.
Eduardo Bravo, Cellerix' CEO added "This capital injection will allow usto continue with the development of all of our programs following the plannedschedule, as well as enabling us to defend and increase Cellerix' leadingposition in the field, helping us to become the first company tocommercialise a cell therapy medicine in Europe".
Cellerix has three products undergoing clinical trials: Ontaril(R)(Cx401) for the treatment of perianal fistulas, currently in Phase III, Cx501for skin regeneration, currently in Phase II and Cx601 for the treatment ofperianal fistulas, in phase II. Ontaril(R), Cx501 and Cx601 have beendesignated orphan status by the European Medicines Agency (EMEA).http://www.cellerix.com.
SOURCE Cellerix SA
